Respiratory Disease Testing Is Estimated To Witness High Growth Owing To Rapid Technological Advancements
Respiratory Disease Testing Respiratory disease testing products effectively diagnoses various respiratory diseases like chronic obstructive pulmonary disease (COPD), lung cancer, asthma, and other lower respiratory tract infections through techniques like pulmonary function tests (PFT), chest imaging and smear tests. PFT helps measure lung capacity and evaluate lung functioning through spirometry and peak flow meter tests, while chest imaging techniques like X-ray, CT scan and MRI helps detect abnormalities in lungs. Moreover, tests like sputum smear examination evaluates presence of harmful bacteria or fungi causing respiratory infections. The global respiratory disease testing market is estimated to be valued at US$ 3232 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Rapid technological advancements is expected to drive the respiratory disease t...